Related Experiment Video
Updated: Jan 30, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors
Abstract:
Protein tyrosine phosphatase SHP2 is an oncoprotein associated with cancer as well as a potential immune modulator because of its role in the programmed cell death PD-L1/PD-1 pathway. In the preceding manuscript, we described the optimization of a fused, bicyclic screening hit for potency, selectivity, and physicochemical properties in order to further expand the chemical diversity of allosteric SHP2 inhibitors. In this manuscript, we describe the further expansion of our approach, morphing the fused, bicyclic system into a novel monocyclic pyrimidinone scaffold through our understanding of SAR and use of structure-based design. These studies led to the identification of SHP394 (1), an orally efficacious inhibitor of SHP2, with high lipophilic efficiency, improved potency, and enhanced pharmacokinetic properties. We also report other pyrimidinone analogues with favorable pharmacokinetic and potency profiles. Overall, this work improves upon our previously described allosteric inhibitors and exemplifies and extends the range of permissible chemical templates that inhibit SHP2 via the allosteric mechanism.
Insights
Researchers developed novel pyrimidinone inhibitors for SHP2, a protein linked to cancer and immune modulation. These orally effective compounds show improved potency and pharmacokinetics, expanding options for allosteric SHP2 inhibition.
Area of Science:
- Medicinal Chemistry
- Oncology
- Immunology
Background:
- Protein tyrosine phosphatase SHP2 is implicated in cancer and immune modulation via the PD-L1/PD-1 pathway.
- Previous work optimized a bicyclic SHP2 inhibitor scaffold.
- Further chemical diversity is needed for allosteric SHP2 inhibitors.
Purpose of the Study:
- To develop novel monocyclic pyrimidinone scaffolds as allosteric SHP2 inhibitors.
- To identify orally efficacious SHP2 inhibitors with improved properties.
- To expand the chemical space for allosteric SHP2 inhibition.
Main Methods:
- Structure-based design and structure-activity relationship (SAR) analysis.
- Optimization of a fused, bicyclic screening hit into a monocyclic pyrimidinone.
- Pharmacokinetic profiling and potency assessment of novel inhibitors.
Main Results:
- Identification of SHP394 (1), an orally efficacious allosteric SHP2 inhibitor.
- SHP394 exhibits high lipophilic efficiency, enhanced potency, and improved pharmacokinetics.
- Several pyrimidinone analogues demonstrated favorable potency and pharmacokinetic profiles.
Conclusions:
- The pyrimidinone scaffold represents a novel and effective template for allosteric SHP2 inhibition.
- This work expands the range of permissible chemical structures for targeting SHP2.
- The developed inhibitors offer potential therapeutic strategies for cancer and immune-related diseases.
More Related Videos
09:57System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
07:04Measuring Uptake of the Glucose Analog, 6-(N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino)-6-Deoxyglucose, in Intact Murine Neural Retina
Published on: March 14, 2025
Related Concept Videos
Amino acids
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Self-Efficacy
Amino Acid Catabolism
Oral Cavity
Teeth: The teeth are the hardest structures in our bodies. Humans have two sets of teeth throughout their lifetime: deciduous (baby) teeth and permanent teeth. Each tooth consists of several parts: the crown (visible part), the root (embedded in the jaw), enamel (hard outer...